Table 1 Open in new tab Baseline...

	Overall	fCAD−	fCAD+
Sex, female	753 (43.9%)	651 (49.5%)	102 (25.6%)
Age	68 (59–76)	67 (58–74)	72 (65–78)
BMI	26.9 (24.2–30.5)	26.8 (24.1–30.5)	27.4 (24.7–30.5)
Symptoms	1019 (59.4%)	782 (59.4%)	237 (59.4%)
Pre-existing disease
Arterial hypertension	1219 (71.1%)	895 (68%)	324 (81.2%)
Hypercholesterolaemia	906 (52.8%)	662 (50.3%)	244 (61.2%)
Arterial fibrillation	248 (14.5%)	176 (13.4%)	72 (18%)
Heart failure	26 (1.5%)	16 (1.2%)	10 (2.5%)
Diabetes	346 (20.2%)	240 (18.2%)	106 (26.6%)
Peripheral arterial disease	101 (5.9%)	64 (4.9%)	37 (9.3%)
Status post-stroke/TIA	130 (7.6%)	77(5.9%)	53 (13.3%)
Pacemaker/ICD/CRT	41 (2.4%)	28 (2.13%)	13 (3.3%)
Family history	390 (22.7%)	305 (23.2%)	85 (21.3%)
Malignancy	255 (14.9%)	196 (14.9%)	59 (14.8%)
Nicotine use	919 (53.6%)	679 (51.6%)	240 (60.1%)
Stopped use	588 (34.3%)	420 (31.9%)	168 (42.1%)
Active use	331 (19.3%)	259 (19.7%)	72 (18%)
Beta-blocker	585 (34.1%)	425 (32.3%)	160 (40.1%)
ACE blocker	359 (20.9%)	262 (19.9%)	97 (24.3%)
AT2 antagonists	528 (30.8%)	385 (29.3%)	143 (35.8%)
Diuretics	591 (34.5%)	419 (31.8%)	172 (43.1%)
Anticoagulation	235 (13.7%)	164 (12.5%)	71 (17.8%)
Warfarin	157 (9.2%)	105 (8%)	52 (13%)
New oral anticoagulants	78 (4.5%)	59 (4.5%)	19 (4.8%)
Aspirin	1046 (61%)	478 (36.3%)	191 (47.9%)
Statin	604 (35.2%)	427 (32.4%)	177 (44.4%)
Cystatin C (RFU), n = 1654	2418.8 (2076.7–2846.1)	2358.6 (2045.9–2764.3)	2595.8 (2241.7–3186.9)
Stress test modality ergometrie	1115 (65%)	894 (68%)	221 (55.4%)
Rate pressure product at rest ^a	11115 (9628–12879)	11050 (9549.8–12816)	11502 (9902–13156)
Rate pressure product at stress^a	30225 (26666–33600)	30432 (26996.8–33852)	29141 (25453–32240)

Overall

fCAD−

fCAD+

n = 1715

n = 1316

n = 399

Sex, female

753 (43.9%)

651 (49.5%)

102 (25.6%)

Age

68 (59–76)

67 (58–74)

72 (65–78)

BMI

26.9 (24.2–30.5)

26.8 (24.1–30.5)

27.4 (24.7–30.5)

Symptoms

1019 (59.4%)

782 (59.4%)

237 (59.4%)

Pre-existing disease

Arterial hypertension

1219 (71.1%)

895 (68%)

324 (81.2%)

Hypercholesterolaemia

906 (52.8%)

662 (50.3%)

244 (61.2%)

Arterial fibrillation

248 (14.5%)

176 (13.4%)

72 (18%)

Heart failure

26 (1.5%)

16 (1.2%)

10 (2.5%)

Diabetes

346 (20.2%)

240 (18.2%)

106 (26.6%)

Peripheral arterial disease

101 (5.9%)

64 (4.9%)

37 (9.3%)

Status post-stroke/TIA

130 (7.6%)

77(5.9%)

53 (13.3%)

Pacemaker/ICD/CRT

41 (2.4%)

28 (2.13%)

13 (3.3%)

Family history

390 (22.7%)

305 (23.2%)

85 (21.3%)

Malignancy

255 (14.9%)

196 (14.9%)

59 (14.8%)

Nicotine use

919 (53.6%)

679 (51.6%)

240 (60.1%)

Stopped use

588 (34.3%)

420 (31.9%)

168 (42.1%)

Active use

331 (19.3%)

259 (19.7%)

72 (18%)

Beta-blocker

585 (34.1%)

425 (32.3%)

160 (40.1%)

ACE blocker

359 (20.9%)

262 (19.9%)

97 (24.3%)

AT2 antagonists

528 (30.8%)

385 (29.3%)

143 (35.8%)

Diuretics

591 (34.5%)

419 (31.8%)

172 (43.1%)

Anticoagulation

235 (13.7%)

164 (12.5%)

71 (17.8%)

Warfarin

157 (9.2%)

105 (8%)

52 (13%)

New oral anticoagulants

78 (4.5%)

59 (4.5%)

19 (4.8%)

Aspirin

1046 (61%)

478 (36.3%)

191 (47.9%)

Statin

604 (35.2%)

427 (32.4%)

177 (44.4%)

Cystatin C (RFU), n = 1654

2418.8 (2076.7–2846.1)

2358.6 (2045.9–2764.3)

2595.8 (2241.7–3186.9)

Stress test modality ergometrie

1115 (65%)

894 (68%)

221 (55.4%)

Rate pressure product at rest ^a

11115 (9628–12879)

11050 (9549.8–12816)

11502 (9902–13156)

Rate pressure product at stress^a

30225 (26666–33600)

30432 (26996.8–33852)

29141 (25453–32240)

	Overall	fCAD−	fCAD+
Sex, female	753 (43.9%)	651 (49.5%)	102 (25.6%)
Age	68 (59–76)	67 (58–74)	72 (65–78)
BMI	26.9 (24.2–30.5)	26.8 (24.1–30.5)	27.4 (24.7–30.5)
Symptoms	1019 (59.4%)	782 (59.4%)	237 (59.4%)
Pre-existing disease
Arterial hypertension	1219 (71.1%)	895 (68%)	324 (81.2%)
Hypercholesterolaemia	906 (52.8%)	662 (50.3%)	244 (61.2%)
Arterial fibrillation	248 (14.5%)	176 (13.4%)	72 (18%)
Heart failure	26 (1.5%)	16 (1.2%)	10 (2.5%)
Diabetes	346 (20.2%)	240 (18.2%)	106 (26.6%)
Peripheral arterial disease	101 (5.9%)	64 (4.9%)	37 (9.3%)
Status post-stroke/TIA	130 (7.6%)	77(5.9%)	53 (13.3%)
Pacemaker/ICD/CRT	41 (2.4%)	28 (2.13%)	13 (3.3%)
Family history	390 (22.7%)	305 (23.2%)	85 (21.3%)
Malignancy	255 (14.9%)	196 (14.9%)	59 (14.8%)
Nicotine use	919 (53.6%)	679 (51.6%)	240 (60.1%)
Stopped use	588 (34.3%)	420 (31.9%)	168 (42.1%)
Active use	331 (19.3%)	259 (19.7%)	72 (18%)
Beta-blocker	585 (34.1%)	425 (32.3%)	160 (40.1%)
ACE blocker	359 (20.9%)	262 (19.9%)	97 (24.3%)
AT2 antagonists	528 (30.8%)	385 (29.3%)	143 (35.8%)
Diuretics	591 (34.5%)	419 (31.8%)	172 (43.1%)
Anticoagulation	235 (13.7%)	164 (12.5%)	71 (17.8%)
Warfarin	157 (9.2%)	105 (8%)	52 (13%)
New oral anticoagulants	78 (4.5%)	59 (4.5%)	19 (4.8%)
Aspirin	1046 (61%)	478 (36.3%)	191 (47.9%)
Statin	604 (35.2%)	427 (32.4%)	177 (44.4%)
Cystatin C (RFU), n = 1654	2418.8 (2076.7–2846.1)	2358.6 (2045.9–2764.3)	2595.8 (2241.7–3186.9)
Stress test modality ergometrie	1115 (65%)	894 (68%)	221 (55.4%)
Rate pressure product at rest ^a	11115 (9628–12879)	11050 (9549.8–12816)	11502 (9902–13156)
Rate pressure product at stress^a	30225 (26666–33600)	30432 (26996.8–33852)	29141 (25453–32240)

Table 1

Open in new tab

Baseline characteristics according to presence (+) or absence (−) of fCAD

	Overall	fCAD−	fCAD+
	n = 1715	n = 1316	n = 399
Sex, female	753 (43.9%)	651 (49.5%)	102 (25.6%)
Age	68 (59–76)	67 (58–74)	72 (65–78)
BMI	26.9 (24.2–30.5)	26.8 (24.1–30.5)	27.4 (24.7–30.5)
Symptoms	1019 (59.4%)	782 (59.4%)	237 (59.4%)
Pre-existing disease
Arterial hypertension	1219 (71.1%)	895 (68%)	324 (81.2%)
Hypercholesterolaemia	906 (52.8%)	662 (50.3%)	244 (61.2%)
Arterial fibrillation	248 (14.5%)	176 (13.4%)	72 (18%)
Heart failure	26 (1.5%)	16 (1.2%)	10 (2.5%)
Diabetes	346 (20.2%)	240 (18.2%)	106 (26.6%)
Peripheral arterial disease	101 (5.9%)	64 (4.9%)	37 (9.3%)
Status post-stroke/TIA	130 (7.6%)	77(5.9%)	53 (13.3%)
Pacemaker/ICD/CRT	41 (2.4%)	28 (2.13%)	13 (3.3%)
Family history	390 (22.7%)	305 (23.2%)	85 (21.3%)
Malignancy	255 (14.9%)	196 (14.9%)	59 (14.8%)
Nicotine use	919 (53.6%)	679 (51.6%)	240 (60.1%)
Stopped use	588 (34.3%)	420 (31.9%)	168 (42.1%)
Active use	331 (19.3%)	259 (19.7%)	72 (18%)
Beta-blocker	585 (34.1%)	425 (32.3%)	160 (40.1%)
ACE blocker	359 (20.9%)	262 (19.9%)	97 (24.3%)
AT2 antagonists	528 (30.8%)	385 (29.3%)	143 (35.8%)
Diuretics	591 (34.5%)	419 (31.8%)	172 (43.1%)
Anticoagulation	235 (13.7%)	164 (12.5%)	71 (17.8%)
Warfarin	157 (9.2%)	105 (8%)	52 (13%)
New oral anticoagulants	78 (4.5%)	59 (4.5%)	19 (4.8%)
Aspirin	1046 (61%)	478 (36.3%)	191 (47.9%)
Statin	604 (35.2%)	427 (32.4%)	177 (44.4%)
Cystatin C (RFU), n = 1654	2418.8 (2076.7–2846.1)	2358.6 (2045.9–2764.3)	2595.8 (2241.7–3186.9)
Stress test modality ergometrie	1115 (65%)	894 (68%)	221 (55.4%)
Rate pressure product at rest ^a	11115 (9628–12879)	11050 (9549.8–12816)	11502 (9902–13156)
Rate pressure product at stress^a	30225 (26666–33600)	30432 (26996.8–33852)	29141 (25453–32240)

	Overall	fCAD−	fCAD+
	n = 1715	n = 1316	n = 399
Sex, female	753 (43.9%)	651 (49.5%)	102 (25.6%)
Age	68 (59–76)	67 (58–74)	72 (65–78)
BMI	26.9 (24.2–30.5)	26.8 (24.1–30.5)	27.4 (24.7–30.5)
Symptoms	1019 (59.4%)	782 (59.4%)	237 (59.4%)
Pre-existing disease
Arterial hypertension	1219 (71.1%)	895 (68%)	324 (81.2%)
Hypercholesterolaemia	906 (52.8%)	662 (50.3%)	244 (61.2%)
Arterial fibrillation	248 (14.5%)	176 (13.4%)	72 (18%)
Heart failure	26 (1.5%)	16 (1.2%)	10 (2.5%)
Diabetes	346 (20.2%)	240 (18.2%)	106 (26.6%)
Peripheral arterial disease	101 (5.9%)	64 (4.9%)	37 (9.3%)
Status post-stroke/TIA	130 (7.6%)	77(5.9%)	53 (13.3%)
Pacemaker/ICD/CRT	41 (2.4%)	28 (2.13%)	13 (3.3%)
Family history	390 (22.7%)	305 (23.2%)	85 (21.3%)
Malignancy	255 (14.9%)	196 (14.9%)	59 (14.8%)
Nicotine use	919 (53.6%)	679 (51.6%)	240 (60.1%)
Stopped use	588 (34.3%)	420 (31.9%)	168 (42.1%)
Active use	331 (19.3%)	259 (19.7%)	72 (18%)
Beta-blocker	585 (34.1%)	425 (32.3%)	160 (40.1%)
ACE blocker	359 (20.9%)	262 (19.9%)	97 (24.3%)
AT2 antagonists	528 (30.8%)	385 (29.3%)	143 (35.8%)
Diuretics	591 (34.5%)	419 (31.8%)	172 (43.1%)
Anticoagulation	235 (13.7%)	164 (12.5%)	71 (17.8%)
Warfarin	157 (9.2%)	105 (8%)	52 (13%)
New oral anticoagulants	78 (4.5%)	59 (4.5%)	19 (4.8%)
Aspirin	1046 (61%)	478 (36.3%)	191 (47.9%)
Statin	604 (35.2%)	427 (32.4%)	177 (44.4%)
Cystatin C (RFU), n = 1654	2418.8 (2076.7–2846.1)	2358.6 (2045.9–2764.3)	2595.8 (2241.7–3186.9)
Stress test modality ergometrie	1115 (65%)	894 (68%)	221 (55.4%)
Rate pressure product at rest ^a	11115 (9628–12879)	11050 (9549.8–12816)	11502 (9902–13156)
Rate pressure product at stress^a	30225 (26666–33600)	30432 (26996.8–33852)	29141 (25453–32240)

Continous variables are presented as median [interquartile range (IQR)]; categorical variables are presented as total number (percentage).

^aFor those who had an ergometry stress.

This Feature Is Available To Subscribers Only